Skip to content

Effect of an alternative to suture in periodontal surgeries

EVALUATION AND COMPARISON OF THE EFFICACY OF AUTOLOGOUS FIBRIN GLUE WITH 4-0 SILK SUTURES IN PERIODONTAL FLAP CLOSURE AND WOUND HEALING - A SPLIT MOUTH RANDOMIZED CONTROLLED TRIAL.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017480
Enrollment
34
Registered
2019-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: FIBRIN GLUE: On the test side the periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to

Sponsors

Dr Neha Pradhan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with periodontitis, with good systemic health and presence of a minimum of 3 teeth with periodontal pocket depth (PPD) of >=6mm and clinical attachment level (CAL) of >=5mm (stage 3 periodontitis as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Condition and published by the American Academy of Periodontology) in at least two quadrants will be selected.

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone periodontal therapy during the previous 6 months, or exhibit poor plaque control after phase I therapy. 2. History of any systemic disease such as diabetes mellitus, hypertension, osteoporosis, unstable or life-threatening conditions, bleeding disorder, undergoing antibiotic or other antimicrobial therapy. 3. Patients on drugs like aspirin, blood thinners and anticoagulant therapy 4. Patients with history of allergy 5. Current or former smokers. 6. Mobility of selected teeth. 7. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Cytokines Parameter for Interleukin 1-β will be assessed in GCF using a commercially available Enzyme-linked immunosorbent assay kit (ELISA), specific for human IL-1 βTimepoint: baseline 7th day after treatment

Secondary

MeasureTime frame
VAS Score by Freyd in 1923 Timepoint: baseline 7th day 14th day 21st day 28th day;Early Wound Healing Index by Watchel et al in 2005 Timepoint: baseline 7th day 14th day 21st day 28th day;Gingival Index by Loe and Silness in 1963 Timepoint: baseline 7th day 14th day 21st day 28th day;Oral Hygiene Index by John C Greene and Jack R Vermilion in 1964 Timepoint: baseline 7th day 14th day 21st day 28th day

Countries

India

Contacts

Public ContactDr Sphoorthi A Belludi

KLE Societys Institute of Dental Sciences

doc_sphoo@yahoo.com9916010380

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026